PTEN is a phosphatase which metabolises PIP 3, the lipid product of PI 3-Kinase, directly
opposing the activation of the oncogenic PI3K/AKT/mTOR signalling network. Accordingly …

Ample data indicate that mutant p53 proteins not only lose their tumour suppressive
functions, but also gain new abilities that promote tumorigenesis. Moreover, recent studies …

Background RNAs within extracellular vesicles (EVs) have potential as diagnostic
biomarkers for patients with cancer and are identified in a variety of biofluids. Glioblastomas …

Epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein and a member of
the tyrosine kinase superfamily receptor. Gliomas are tumors originating from glial cells …

Context.—The diagnosis and clinical management of patients with diffuse gliomas (DGs)
have evolved rapidly over the past decade with the emergence of molecular biomarkers that …

Malignant gliomas represent one of the most devastating human diseases. Primary
treatment of these tumours involves surgery to achieve tumour debulking, followed by a …

The epidermal growth factor receptor vIII mutant (EGFRvIII) is found in∼ 50% of all EGFR‐
amplified glioblastomas and constitutes a tumor‐specific therapeutic target. To assess …

Despite extensive efforts in research and therapeutics, achieving longer survival for patients
with glioblastoma (GBM) remains a formidable challenge. Furthermore, because of rapid …

Glioblastomas (GBMs), the most common primary malignancies of the central nervous
system, are highly aggressive and heterogeneous, and remain a dramatic therapeutic …

Tumor-associated macrophages (TAMs) originate as circulating monocytes, and are
recruited to gliomas, where they facilitate tumor growth and migration. Understanding the …